224 related articles for article (PubMed ID: 32709869)
21. A concise review of VEGF, PDGF, FGF, Notch, angiopoietin, and HGF signalling in tumor angiogenesis with a focus on alternative approaches and future directions.
Vimalraj S
Int J Biol Macromol; 2022 Nov; 221():1428-1438. PubMed ID: 36122781
[TBL] [Abstract][Full Text] [Related]
22. Iloprost up-regulates vascular endothelial growth factor expression in human dental pulp cells in vitro and enhances pulpal blood flow in vivo.
Limjeerajarus CN; Osathanon T; Manokawinchoke J; Pavasant P
J Endod; 2014 Jul; 40(7):925-30. PubMed ID: 24935537
[TBL] [Abstract][Full Text] [Related]
23. Tanshinone IIA inhibits β-catenin/VEGF-mediated angiogenesis by targeting TGF-β1 in normoxic and HIF-1α in hypoxic microenvironments in human colorectal cancer.
Sui H; Zhao J; Zhou L; Wen H; Deng W; Li C; Ji Q; Liu X; Feng Y; Chai N; Zhang Q; Cai J; Li Q
Cancer Lett; 2017 Sep; 403():86-97. PubMed ID: 28602978
[TBL] [Abstract][Full Text] [Related]
24. Distinct role of fibroblast growth factor-2 and vascular endothelial growth factor on tumor growth and angiogenesis.
Giavazzi R; Sennino B; Coltrini D; Garofalo A; Dossi R; Ronca R; Tosatti MP; Presta M
Am J Pathol; 2003 Jun; 162(6):1913-26. PubMed ID: 12759248
[TBL] [Abstract][Full Text] [Related]
25. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
Huang SW; Lien JC; Kuo SC; Huang TF
Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
[TBL] [Abstract][Full Text] [Related]
26. gamma-Hydroxybutyric acid and 5-fluorouracil, metabolites of UFT, inhibit the angiogenesis induced by vascular endothelial growth factor.
Basaki Y; Chikahisa L; Aoyagi K; Miyadera K; Yonekura K; Hashimoto A; Okabe S; Wierzba K; Yamada Y
Angiogenesis; 2001; 4(3):163-73. PubMed ID: 11911014
[TBL] [Abstract][Full Text] [Related]
27. Dual roles of endothelial FGF-2-FGFR1-PDGF-BB and perivascular FGF-2-FGFR2-PDGFRβ signaling pathways in tumor vascular remodeling.
Hosaka K; Yang Y; Nakamura M; Andersson P; Yang X; Zhang Y; Seki T; Scherzer M; Dubey O; Wang X; Cao Y
Cell Discov; 2018; 4():3. PubMed ID: 29423271
[TBL] [Abstract][Full Text] [Related]
28. PDGF-CC underlies resistance to VEGF-A inhibition and combinatorial targeting of both suppresses pathological angiogenesis more efficiently.
Zheng L; Zhao C; Du Y; Lin X; Jiang Y; Lee C; Tian G; Mi J; Li X; Chen Q; Ye Z; Huang L; Wang S; Ren X; Xing L; Chen W; Huang D; Gao Z; Zhang S; Lu W; Tang Z; Wang B; Ju R; Li X
Oncotarget; 2016 Nov; 7(47):77902-77915. PubMed ID: 27788490
[TBL] [Abstract][Full Text] [Related]
29. The potential of fibroblast growth factor/fibroblast growth factor receptor signaling as a therapeutic target in tumor angiogenesis.
Ronca R; Giacomini A; Rusnati M; Presta M
Expert Opin Ther Targets; 2015; 19(10):1361-77. PubMed ID: 26125971
[TBL] [Abstract][Full Text] [Related]
30. R Regulation of tumor angiogenesis and metastasis by FGF and PDGF signaling pathways.
Cao Y; Cao R; Hedlund EM
J Mol Med (Berl); 2008 Jul; 86(7):785-9. PubMed ID: 18392794
[TBL] [Abstract][Full Text] [Related]
31. PDGF-C induces maturation of blood vessels in a model of glioblastoma and attenuates the response to anti-VEGF treatment.
di Tomaso E; London N; Fuja D; Logie J; Tyrrell JA; Kamoun W; Munn LL; Jain RK
PLoS One; 2009; 4(4):e5123. PubMed ID: 19352490
[TBL] [Abstract][Full Text] [Related]
32. VEGF-A/VEGFR-2 and FGF-2/FGFR-1 but not PDGF-BB/PDGFR-β play important roles in promoting immature and inflammatory intraplaque angiogenesis.
Mao Y; Liu X; Song Y; Zhai C; Zhang L
PLoS One; 2018; 13(8):e0201395. PubMed ID: 30125282
[TBL] [Abstract][Full Text] [Related]
33. The selective class III/V receptor tyrosine kinase inhibitor SU11657 inhibits tumor growth and angiogenesis in experimental neuroblastomas grown in mice.
Bäckman U; Christofferson R
Pediatr Res; 2005 May; 57(5 Pt 1):690-5. PubMed ID: 15718357
[TBL] [Abstract][Full Text] [Related]
34. Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors.
Homsi J; Daud AI
Cancer Control; 2007 Jul; 14(3):285-94. PubMed ID: 17615535
[TBL] [Abstract][Full Text] [Related]
35. Reversal of portal hypertension and hyperdynamic splanchnic circulation by combined vascular endothelial growth factor and platelet-derived growth factor blockade in rats.
Fernandez M; Mejias M; Garcia-Pras E; Mendez R; Garcia-Pagan JC; Bosch J
Hepatology; 2007 Oct; 46(4):1208-17. PubMed ID: 17654489
[TBL] [Abstract][Full Text] [Related]
36. Differential roles of PDGFR-alpha and PDGFR-beta in angiogenesis and vessel stability.
Zhang J; Cao R; Zhang Y; Jia T; Cao Y; Wahlberg E
FASEB J; 2009 Jan; 23(1):153-63. PubMed ID: 18827023
[TBL] [Abstract][Full Text] [Related]
37. VEGF and FGF-2: Promising targets for the treatment of respiratory disorders.
Laddha AP; Kulkarni YA
Respir Med; 2019 Sep; 156():33-46. PubMed ID: 31421589
[TBL] [Abstract][Full Text] [Related]
38. Targeting of tumor growth and angiogenesis underlies the enhanced antitumor activity of lenvatinib in combination with everolimus.
Matsuki M; Adachi Y; Ozawa Y; Kimura T; Hoshi T; Okamoto K; Tohyama O; Mitsuhashi K; Yamaguchi A; Matsui J; Funahashi Y
Cancer Sci; 2017 Apr; 108(4):763-771. PubMed ID: 28107584
[TBL] [Abstract][Full Text] [Related]
39. Construction of a disulfide-stabilized diabody against fibroblast growth factor-2 and the inhibition activity in targeting breast cancer.
Cai Y; Zhang J; Lao X; Jiang H; Yu Y; Deng Y; Zhong J; Liang Y; Xiong L; Deng N
Cancer Sci; 2016 Aug; 107(8):1141-50. PubMed ID: 27251178
[TBL] [Abstract][Full Text] [Related]
40. The vascular disrupting agent BNC105 potentiates the efficacy of VEGF and mTOR inhibitors in renal and breast cancer.
Inglis DJ; Lavranos TC; Beaumont DM; Leske AF; Brown CK; Hall AJ; Kremmidiotis G
Cancer Biol Ther; 2014; 15(11):1552-60. PubMed ID: 25482941
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
